lindas have a posse
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That's exactly what happened with the SAP amendment.
Landmark Trial Data gets approved. Thanks again for the insight, Notacure!
Landmark Trial Results!
Landmark Trial Results!
MHRA Trial Endorsement (PIP)!
Innovative MHRA-endorsed Manufacturing!
Global Patent Protection!
My 500K shares should be worth $40M or more once Northwest Biotherapeutics obtains global approval on nGBM and rGBM indications.
I see no reason to sell my shares since I can borrow against them once NWBO are off OTC.
In my personal opinion as a retail investor representing myself alone, and not providing investment advice, longs must focus upon the deep value present in Northwest Biotherapeutics stock!
Billionaire Robert Hefner agrees:
Our Northwest Biotherapeutics (NWBO) investee “partner” likely has just made one of the biggest breakthroughs in the history of cancer. We know that is a really big statement so why do we at GHK believe that is possible? Because we believe the doors through which major cancer breakthroughs must pass are the human immune system, immunotherapies and personalized vaccines and NWBO has just leaped through those doors with its personalized DCVax vaccine made from your own cells.
You can argue about trial statistics until the cows come home but the bottom line is 1) people living longer 2) quality of life during treatments and 3) the cost of treatments.
During NWBO’s 16-year Phase III trial to treat glioblastoma (GBM), one of the most difficult and lethal of all solid tumor cancers 1) more people lived longer, 2) it is safe with virtually no side effects occurring and 3) NWBO estimates treatments will cost about half as much as Standard of Care chemotherapy and radiation treatments. So for the first time ever, GBM patients can have hope! And can hope like prayer increase the effectiveness and energy of the immune system? We think so.
We are aware we stuck our necks out when we said “possibly one of the biggest breakthroughs in the history of cancer”. So we have listed below our three principle reasons so you can decide for yourself:
After 417 failed GBM trials treating 31,952 patents over decades, DCVax-L is first treatment that gives GBM patients a meaningful chance to live longer, some now living 9 to as many as 19 years and counting.
DCVax was conceived and created not for glioblastoma alone but as a personalized tool of your own immune system to defeat all solid tumor cancers and that’s 90% of all cancers.
Since DCVax’s creation NWBO has amassed an enormous rich databank containing masses of information on patients, treatments, and DCVax’s use against 15 different solid tumor cancers that has not yet been analyzed by artificial intelligence (AI). We believe that in the near future when these vast amounts of data and information are teamed with AI and some of the world’s leading scientists and doctors that future generations of DCVax vaccines and protocols will experience great leaps forward in effectiveness at lower and lower costs for 90% of all cancers.
So to sum up, we believe NWBO with its DCVax immunotherapy personalized vaccines has leaped through the doors and will play a vital role in humanities great drive to defeat cancer once and for all.
Dr. Ashkan is the genius behind this viral vid of him performing brain surgery while his patient was awakened to play the violin…mid-surgery. He told me he champions DCVax-L bc of trial data along with what he’s seen first-hand from his patients. $NWBOhttps://t.co/XFTeSPFtH5
— Wade Kovash (@wkovash) June 6, 2022
Watch one of the world’s preeminent neurosurgeons explain the significance of $NWBO ‘s Phase III trial of DCVax-L. The results are groundbreaking and represent an enormous advancement in one of the most tragic cancers. https://t.co/eQw5tAsivK
— Wade Kovash (@wkovash) June 6, 2022
Value investors like to buy before others.
If you feel awareness of Northwest should be improved then why don't you utilize your extensive resources by contracting the editors at all major US newspapers?
Many of us have done a lot to spread the word about DCVax yet it seems others are content with their baseless disparagement of our world-class management.
Northwest Biotherapeutics has a plethora of angel investors who will back the firm come hell or high water. The debt ceiling has absolutely no bearing on the billions in revenue DCVax will bring to Northwest Biotherapeutics shareholders. It has no impact on the ability of Merck to engage in partnerships or buyouts given their cash on hand, significant equity position, as well as stellar credit rating. Some are always looking to manufacture negative sentiment while management are focused on capturing the untapped all solid tumors market.
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
https://pubmed.ncbi.nlm.nih.gov/37129737/
http://nwbio.com/wp-content/uploads/NWBT-GBM-Summit-slides-3-15-23.pdf
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169815671
I have not seen any filings showing GHK's position in NWBO. Family offices are generally exempt from SEC disclosures.
If you believe that management are making selective disclosures to shareholders which would be RegFD violation then perhaps you should file a lawsuit or an SEC complaint. Management are quite adept at dealing with these distractions.
Trillion dollar technology.
Northwest Biotherapeutics has saved many lives. It seems they have a cure for cancer. They're meeting every milestone it seems with approval right around the corner.
DCVax will achieve MHRA approval this year. That personal belief has not changed. I am buying more next week.
Submitting an application isn't a material event in the eyes of the SEC. I don't really care what people post anonymously on this forum regarding interpretations of what investor relations may have stated on this matter. Management clearly are not being verbose which signifies confidence.
Balderdash. Management has certainly shared data with regulators otherwise how else could MHRA approve the PIP?
Back and forth discussions with regulators are not disclosed. Drug approvals are largely private. Though any negative feedback would require a disclosure. We have had nothing but good news.
Landmark Trial Results!
MHRA Trial Endorsement (PIP)!
Innovative MHRA-endorsed Manufacturing!
Global Patent Protection!
My 500K shares should be worth $40M or more once Northwest Biotherapeutics obtains global approval on nGBM and rGBM indications.
I see no reason to sell my shares since I can borrow against them once NWBO are off OTC.
In my personal opinion as a retail investor representing myself alone, and not providing investment advice, longs must focus upon the deep value present in Northwest Biotherapeutics stock!
Billionaire Robert Hefner agrees:
Our Northwest Biotherapeutics (NWBO) investee “partner” likely has just made one of the biggest breakthroughs in the history of cancer. We know that is a really big statement so why do we at GHK believe that is possible? Because we believe the doors through which major cancer breakthroughs must pass are the human immune system, immunotherapies and personalized vaccines and NWBO has just leaped through those doors with its personalized DCVax vaccine made from your own cells.
You can argue about trial statistics until the cows come home but the bottom line is 1) people living longer 2) quality of life during treatments and 3) the cost of treatments.
During NWBO’s 16-year Phase III trial to treat glioblastoma (GBM), one of the most difficult and lethal of all solid tumor cancers 1) more people lived longer, 2) it is safe with virtually no side effects occurring and 3) NWBO estimates treatments will cost about half as much as Standard of Care chemotherapy and radiation treatments. So for the first time ever, GBM patients can have hope! And can hope like prayer increase the effectiveness and energy of the immune system? We think so.
We are aware we stuck our necks out when we said “possibly one of the biggest breakthroughs in the history of cancer”. So we have listed below our three principle reasons so you can decide for yourself:
After 417 failed GBM trials treating 31,952 patents over decades, DCVax-L is first treatment that gives GBM patients a meaningful chance to live longer, some now living 9 to as many as 19 years and counting.
DCVax was conceived and created not for glioblastoma alone but as a personalized tool of your own immune system to defeat all solid tumor cancers and that’s 90% of all cancers.
Since DCVax’s creation NWBO has amassed an enormous rich databank containing masses of information on patients, treatments, and DCVax’s use against 15 different solid tumor cancers that has not yet been analyzed by artificial intelligence (AI). We believe that in the near future when these vast amounts of data and information are teamed with AI and some of the world’s leading scientists and doctors that future generations of DCVax vaccines and protocols will experience great leaps forward in effectiveness at lower and lower costs for 90% of all cancers.
So to sum up, we believe NWBO with its DCVax immunotherapy personalized vaccines has leaped through the doors and will play a vital role in humanities great drive to defeat cancer once and for all.
Dr. Ashkan is the genius behind this viral vid of him performing brain surgery while his patient was awakened to play the violin…mid-surgery. He told me he champions DCVax-L bc of trial data along with what he’s seen first-hand from his patients. $NWBOhttps://t.co/XFTeSPFtH5
— Wade Kovash (@wkovash) June 6, 2022
Watch one of the world’s preeminent neurosurgeons explain the significance of $NWBO ‘s Phase III trial of DCVax-L. The results are groundbreaking and represent an enormous advancement in one of the most tragic cancers. https://t.co/eQw5tAsivK
— Wade Kovash (@wkovash) June 6, 2022
I didn't open any new accounts.
Why was my jail time extended by 4 days? I was supposed to be released tomorrow.
Glad you agree that Linda Powers seeks maximum benefit for shareholders as well as patients.
Have a great evening, Happy!
Then obviously we are buying Oncovir.
He has a masters in chemical engineering and told me PolyICLC contains lots of hydrocarbon bonds.
Family member who works in Boston in the field after I sent him the link https://pubchem.ncbi.nlm.nih.gov/compound/136033680:
"I don't think hydrocarbons are very easy to manufacture. High cost at the moment cause there isn't catalysts for it."
DCVax by itself showed amazing results in compassionate use.
http://nwbio.com/wp-content/uploads/NWBT-GBM-Summit-slides-3-15-23.pdf
Buy Now or Cry Later!
Thank you for putting together such amazing DD!
Buying Oncovir after MHRA approval makes the most sense.
Technical analysis isn't useful on a highly manipulated stock though I believe that fundamentals will take over once we have regulatory approval. At that point all short narratives will errode entirely while the foreword looking nature of markets will finally come to realize the billions in revenue produced from one small factory less than 100K square feet in size. We have no upper bound in my opinion considering the trillion plus dollar greenfield oncology market we are about start accessing with the most deadly Glioblastoma. Best to you and all longs that never gave up over these many years of gaslighting!
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
https://www.researchsquare.com/article/rs-2591941/v1
http://nwbio.com/wp-content/uploads/NWBT-GBM-Summit-slides-3-15-23.pdf
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169815671
We will be at $25 quickly after MHRA approval which I believe will occur this year. Longs cannot let themselves get gaslight by the spoofing market makers or short seller cranks shilling for Novocure.
In every bear market there are companies that generate large returns. I believe we are one of those stocks as the demand for a cancer cure isn't cyclical or by in large elastic. The demand will always be present while the inordinate efforts made on ensuring efficient manufacturing I think will help keep our vaccine priced at a level where there's a high degree of accessibility. That in turn will drive revenue if we can avoid the bottlenecks present in CAR-T manufacturing for example while keeping our vaccine at an reasonable price of under $250K. I have never been more excited!
Management cannot stop criminals from spoofing considering the criminals control FINRA.
Glad to help bio. I didn't originally post that paper but I will keep posting it as often as possible.
Wash trading.
This is the way.
I have spoken with Dave regarding issuing guidance on regulatory approval. I don't know if it will be forthcoming. Regardless the worst case scenario of an application submitted this month or May then approval by July or August isn't concerning to me since I will own this stock for another 5 years at a minimum. The consternation regarding this period we are in now makes zero sense as management have had nothing but success.
Have they not earned our trust?
You have no evidence supporting your assertion that management are behind schedule.
Shareholders are not served by arguing that management are late nor are patients. In reality at every step of this process management have executed flawlessly with zero rebuke from regulators. So what's the problem, really, when Sawston has cold storage for $50 billion in DCVax doses? That isn't going idle once we get approval this year.
None of this matters for long-term shareholder.
SEC does not require companies disclose the submission of a new drug application. Linda Powers isn't verbose in her strategy. It has been nothing but flawless execution. I trust in their judgment of the process.